Miccio Joseph A, Talcott Wesley J, Patel Timil, Park Henry S, Cecchini Michael, Salem Ronald R, Khan Sajid A, Stein Stacey, Kortmansky Jeremy S, Lacy Jill, Narang Amol, Herman Joseph, Jabbour Salma K, Hallemeier Christopher L, Johung Kimberly, Jethwa Krishan R
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT 06520, USA.
Department of Medical Oncology, Yale School of Medicine, New Haven, CT 06520, USA.
Clin Transl Radiat Oncol. 2020 Dec 16;27:15-23. doi: 10.1016/j.ctro.2020.12.003. eCollection 2021 Mar.
Margin-negative (R0) resection is the only potentially curative treatment for patients with pancreatic ductal adenocarcinoma (PDAC). Pre-operative multi-agent chemotherapy alone (MAC) or MAC followed by pre-operative radiotherapy (MAC + RT) may be used to improve resectability and potentially survival. However, the optimal pre-operative regimen is unknown.
Patients with non-metastatic PDAC from 2006 to 2016 who received pre-operative MAC or MAC + RT before oncologic resection were identified in the National Cancer Database. Univariable and multivariable (MVA) associates with R0 resection were identified with logistic regression, and survival was analyzed secondarily with the Kaplan Meier method and Cox regression analysis.
4,599 patients were identified (MAC: 3,109, MAC + RT: 1,490). Compared to those receiving MAC, patients receiving MAC + RT were more likely to have cT3-4 disease (76% vs 64%, p < 0.001) and cN + disease (33% vs 29%, p = 0.010), but were less likely to have ypT3-4 disease (59% vs 74%, p < 0.001) and ypN + disease (32% vs 55%, p < 0.001) and more likely to have a pathologic complete response (5% vs 2%, p < 0.001) and R0 resection (86% vs 80%, p < 0.001). On MVA, MAC + RT (OR 1.58, 95% CI 1.33-1.89, p < 0.001), evaluation at an academic center (OR 1.33, 95% CI 1.14-1.56, p < 0.001), and female sex (OR 1.43, 95% CI 1.23-1.67, p < 0.001) were associated with higher odds of R0 resection, while cT3-4 disease (OR 0.81, 95% CI 0.68-0.96, p = 0.013) was associated with lower odds of R0 resection.
For patients with localized PDAC who receive pre-operative MAC, the addition of pre-operative RT was associated with improved rates of R0 resection and pathologic response.
切缘阴性(R0)切除是胰腺导管腺癌(PDAC)患者唯一可能治愈的治疗方法。单独术前多药化疗(MAC)或MAC后行术前放疗(MAC + RT)可用于提高可切除性并可能延长生存期。然而,最佳的术前方案尚不清楚。
在国家癌症数据库中识别出2006年至2016年接受肿瘤切除术前MAC或MAC + RT的非转移性PDAC患者。通过逻辑回归确定与R0切除相关的单变量和多变量(MVA)因素,并使用Kaplan-Meier方法和Cox回归分析对生存期进行二次分析。
共识别出4599例患者(MAC组:3109例,MAC + RT组:1490例)。与接受MAC的患者相比,接受MAC + RT的患者更可能患有cT3-4期疾病(76%对64%,p < 0.001)和cN +期疾病(33%对29%,p = 0.010),但ypT3-4期疾病(59%对74%,p < 0.001)和ypN +期疾病(32%对55%,p < 0.001)的可能性较小,且更可能出现病理完全缓解(5%对2%,p < 0.001)和R0切除(86%对80%,p < 0.001)。在多变量分析中,MAC + RT(比值比1.58,95%置信区间1.33 - 1.89,p < 0.001)、在学术中心接受评估(比值比1.33,95%置信区间1.14 - 1.56,p < 0.001)和女性(比值比1.43,95%置信区间1.23 - 1.67,p < 0.001)与R0切除几率较高相关,而cT3-4期疾病(比值比0.81,95%置信区间0.68 - 0.96,p = 0.013)与R0切除几率较低相关。
对于接受术前MAC的局限性PDAC患者,加用术前放疗与R0切除率和病理反应的改善相关。